Long-term superior performance of a stem cell/hepatocyte device for the treatment of acute liver failure.

Cell-based technologies to support/restore organ function represent one of the most promising avenues in the treatment of acute liver failure (ALF). Recently, mesenchymal stem cells (MSCs) have been reported as a new therapeutic for inflammatory conditions. Here, we demonstrate the efficacy of MSCs, when cocultured with hepatocytes, to provide combination hepatic and antiinflammatory therapy in the setting of ALF. MSCs were shown to have multiple beneficial effects in vitro that were relevant in a therapeutic context, including (1) hepatocellular functional support, (2) secretion of molecules that inhibit hepatocyte apoptosis, and (3) modulation of an acute phase response by hepatocytes cultured in ALF-induced serum. In addition, we show that the MSC secretome is dynamically changed in response to serum exposure from ALF rats. We then conducted a therapeutic trial of liver assist devices (LADs). LADs containing cocultures of MSCs and hepatocytes provided a greater survival benefit compared to other coculture and monocellular control LADs. Treatment with MSC-hepatocyte devices was associated with specific improvements in hepatic functional and histological parameters as well as decreasing inflammatory serum cytokine levels, validating a combined therapeutic effect. Moreover, MSC coculture reduced the overall cell mass of the device by an order of magnitude. These findings demonstrate the importance of nonparenchymal cells in the cellular composition of LADs, and strongly support the integration of MSCs into hepatocyte-coculture-based LADs as a potential destination therapy for ALF.

[1]  M. Yarmush,et al.  A new technique for primary hepatocyte expansion in vitro , 2008, Biotechnology and bioengineering.

[2]  M. Yarmush,et al.  Mesenchymal stem cell–derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo , 2008, Hepatology.

[3]  S. Bhatia,et al.  Microscale culture of human liver cells for drug development , 2008, Nature Biotechnology.

[4]  M. Yarmush,et al.  Immunomodulation of activated hepatic stellate cells by mesenchymal stem cells. , 2007, Biochemical and biophysical research communications.

[5]  M. Yarmush,et al.  Mesenchymal Stem Cell-Derived Molecules Reverse Fulminant Hepatic Failure , 2007, PloS one.

[6]  T. Ochiya,et al.  Adipose tissue‐derived mesenchymal stem cells as a source of human hepatocytes , 2007, Hepatology.

[7]  L. Ortiz,et al.  Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury , 2007, Proceedings of the National Academy of Sciences.

[8]  Florian Tögel,et al.  Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury. , 2007, American journal of physiology. Renal physiology.

[9]  P. Angeli,et al.  Renal failure and bacterial infections in patients with cirrhosis: Epidemiology and clinical features , 2007, Hepatology.

[10]  R. Tompkins,et al.  A bioartificial liver device secreting interleukin-1 receptor antagonist for the treatment of hepatic failure in rats. , 2007, The Journal of surgical research.

[11]  Mehmet Toner,et al.  Treatment of fulminant hepatic failure in rats using a bioartificial liver device containing porcine hepatocytes producing interleukin-1 receptor antagonist. , 2006, Tissue engineering.

[12]  S. Strom,et al.  Historical aspects of hepatocyte transplantation. , 2006, Transplantation proceedings.

[13]  J. Ingwall,et al.  Evidence supporting paracrine hypothesis for Akt‐modified mesenchymal stem cell‐mediated cardiac protection and functional improvement , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  L. Griffith,et al.  Capturing complex 3D tissue physiology in vitro , 2006, Nature Reviews Molecular Cell Biology.

[15]  Martin L Yarmush,et al.  Liver endothelial cells promote LDL‐R expression and the uptake of HCV‐like particles in primary rat and human hepatocytes , 2006, Hepatology.

[16]  J. Millis,et al.  Technology Insight: liver support systems , 2005, Nature Clinical Practice Gastroenterology &Hepatology.

[17]  J. Ingwall,et al.  Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells , 2005, Nature Medicine.

[18]  Arul Jayaraman,et al.  Evaluation of an in vitro model of hepatic inflammatory response by gene expression profiling. , 2005, Tissue engineering.

[19]  O. Lee,et al.  In vitro hepatic differentiation of human mesenchymal stem cells , 2004, Hepatology.

[20]  Sangeeta N Bhatia,et al.  Exploring interactions between rat hepatocytes and nonparenchymal cells using gene expression profiling , 2004, Hepatology.

[21]  R. Silverstein.  Review: D-Galactosamine lethality model: scope and limitations , 2004 .

[22]  Mauro Salizzoni,et al.  Prospective, Randomized, Multicenter, Controlled Trial of a Bioartificial Liver in Treating Acute Liver Failure , 2004, Annals of surgery.

[23]  L. Ridolfi,et al.  First Report of Cryopreserved Human Hepatocytes Based Bioartificial Liver Successfully Used as a Bridge to Liver Transplantation , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[24]  Kiyohito Yagi,et al.  Maintenance of hepatocyte functions by coculture with bone marrow stromal cells. , 2004, Journal of bioscience and bioengineering.

[25]  R. Silverstein.  D-galactosamine lethality model: scope and limitations. , 2004, Journal of endotoxin research.

[26]  I M Sauer,et al.  Clinical extracorporeal hybrid liver support – phase I study with primary porcine liver cells , 2003, Xenotransplantation.

[27]  Mehmet Toner,et al.  Efficacy of an extracorporeal flat-plate bioartificial liver in treating fulminant hepatic failure. , 2003, The Journal of surgical research.

[28]  Christian Gluud,et al.  Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: a systematic review. , 2003, JAMA.

[29]  William M. Lee.  Acute Liver Failure in the United States , 2003, Annals of Internal Medicine.

[30]  W Höhn,et al.  A Method to assess Biochemical Activity of Liver Cells during Clinical Application of Extracorporeal Hybrid Liver Support , 2002, The International journal of artificial organs.

[31]  G. Mazariegos,et al.  Clinical and laboratory evaluation of the safety of a bioartificial liver assist device for potential transmission of porcine endogenous retrovirus. , 2002, Transplantation.

[32]  G. Mazariegos,et al.  Safety Observations in Phase I Clinical Evaluation of the Excorp Medical Bioartificial Liver Support System after the First Four Patients , 2001, ASAIO journal.

[33]  S. Bhatia,et al.  Xenobiotic metabolism by cultured primary porcine hepatocytes. , 2000, Tissue engineering.

[34]  M L Yarmush,et al.  Probing heterotypic cell interactions: hepatocyte function in microfabricated co-cultures. , 1998, Journal of biomaterials science. Polymer edition.

[35]  M. Sefton,et al.  Tissue engineering. , 1998, Journal of cutaneous medicine and surgery.

[36]  K. Maezono,et al.  Effect of alanine on D‐galactosamine‐induced acute liver failure in rats , 1996, Hepatology.

[37]  R. Tompkins,et al.  Hepatocyte function and extracellular matrix geometry: long‐term culture in a sandwich configuration , 1989, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.